Short Interest in CytoDyn Inc. (OTCMKTS:CYDY) Increases By 6.4%

CytoDyn Inc. (OTCMKTS:CYDY) saw a significant increase in short interest in the month of January. As of January 31st, there was short interest totalling 22,639,300 shares, an increase of 6.4% from the January 15th total of 21,272,500 shares. Based on an average daily trading volume, of 11,699,700 shares, the days-to-cover ratio is currently 1.9 days.

CytoDyn Stock Performance

CytoDyn stock traded up $0.00 during trading on Monday, reaching $0.22. The company had a trading volume of 1,991,689 shares, compared to its average volume of 4,342,034. The firm’s 50-day simple moving average is $0.16 and its 200 day simple moving average is $0.15. The firm has a market capitalization of $267.36 million, a PE ratio of -21.73 and a beta of 0.01. CytoDyn has a 1-year low of $0.10 and a 1-year high of $0.32.

CytoDyn Company Profile

CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.